RUBY - Rubius Therapeutics, Inc.
| Previous Close | 16.31 |
| Open | 16.33 |
| Bid | 11.19 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 16.08 - 17.09 |
| 52 Week Range | 12.70 - 33.01 |
| Volume | 274,686 |
| Avg. Volume | 316,408 |
| Market Cap | 1.332B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.60 |
| Earnings Date | Mar 28, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.75 |
- Simply Wall St.•19 hours ago
How Many Insiders Bought Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! It is not uncommon to see companies perform well inRead More...
- GlobeNewswire•23 hours ago
Rubius Therapeutics Appoints Natalie Holles to its Board of Directors and Greg Whitehead as Senior Vice President and Chief Quality Officer
Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced the appointment of Natalie Holles, president and chief operating officer of Audentes Therapeutics, as a member of the company’s board of directors and Greg Whitehead as senior vice president and chief quality officer. Rubius further announced that Roger Pomerantz, M.D., who has served as a board member since Rubius’ founding, has decided not to stand for reelection with his board membership ending by June 2019.
- GlobeNewswire•7 days ago
Rubius Therapeutics to Announce Fourth Quarter and Full-Year 2018 Financial Results
CAMBRIDGE, Mass., March 19, 2019 -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering.
- GlobeNewswire•15 days ago
Rubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of Phenylketonuria
Rubius Therapeutics, Inc. (RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for RTX-134, an allogeneic, off-the-shelf cellular therapy for the potential treatment of patients with phenylketonuria (PKU). The Phase 1b clinical trial is expected to be the first-ever clinical investigation of genetically engineered red blood cells.
- GlobeNewswire•27 days ago
Rubius Therapeutics Announces Poster Presentations at the 2019 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass., Feb. 27, 2019 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an.
- GlobeNewswire•last month
Rubius Therapeutics to Participate at Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 19, 2019 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an.
- GlobeNewswire•3 months ago
Rubius Therapeutics Highlights Upcoming 2019 Milestones at the 37th Annual J.P. Morgan Healthcare Conference
Rubius Therapeutics, Inc. (RUBY), a biotechnology company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced anticipated 2019 development milestones. Pablo J. Cagnoni, M.D., chief executive officer, will present these updates and review 2018 accomplishments today at 9:00 a.m. PT at the 37th Annual J.P. Morgan Healthcare Conference. “At Rubius Therapeutics, we made tremendous progress in 2018, transforming from a privately-held company into a publicly-traded, fully integrated research and development organization that is advancing a robust pipeline of Red Cell Therapeutics™ for the potential treatment of rare enzyme deficiencies, cancer and autoimmune diseases,” said Dr. Cagnoni.
- GlobeNewswire•3 months ago
Rubius Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Dec. 27, 2018 -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies,.
- Bloomberg•3 months ago
Qatar Fund Building Venture Capital Unit for U.S. Startups
The Qatar Investment Authority, created to handle the windfall from the country’s gas and oil exports, has invested in companies including Foursquare Labs Inc., biotech firm Rubius Therapeutics Inc., Homology Medicines Inc., Thoughtspot Inc. and Grail Inc., said the people, asking not to be identified because the deals are private.
- American City Business Journals•4 months ago
Cambridge's Moderna sets record with $604M IPO
The Cambridge biotech shattered records on Thursday night when it announced it had raised more than $604 million in an IPO, the largest ever in the sector.
- GlobeNewswire•4 months ago
Rubius Therapeutics to Present at Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., Nov. 19, 2018 -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies,.
- GlobeNewswire•5 months ago
Rubius Therapeutics to Participate in Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 06, 2018 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies,.
- GlobeNewswire•5 months ago
Rubius Therapeutics to Announce Third Quarter 2018 Financial Results
CAMBRIDGE, Mass., Nov. 05, 2018 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, plans to.
- ACCESSWIRE•6 months ago
Biotech Market is Rolling and These Companies Need to Be on Your Radar
HENDERSON, NV / ACCESSWIRE / September 24, 2018 / Now that the biotechnology sector is well on its way to bouncing back after bottoming in May 2018, some investors may feel like they missed out. Don't ...
- Zacks•6 months ago
Rubius (RUBY) in Focus: Stock Moves 8.7% Higher
Rubius (RUBY) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
- Investor's Business Daily•7 months ago
How This Biotech IPO Is Facing Off Vs. BioMarin In Metabolic Disease
Rubius Therapeutics could rival BioMarin Pharmaceutical in treating a metabolic disorder but, first, the duo will face a dark horse candidate in the form of Synlogic.
